Julie Krop
Chief Tech/Sci/R&D Officer at PURETECH HEALTH PLC
Net worth: - $ as of 2024-03-30
Profile
Julie Krop is currently serving as the Independent Director at Aquestive Therapeutics, Inc., Chief Medical Officer at Puretech Health LLC, and Chief Medical Officer at PureTech Health Plc.
Previously, she worked as the Associate Director at Pfizer Inc., Director-Clinical Research at Millennium Pharmaceuticals, Inc., VP-Clinical Development & Regulatory Affairs at Stryker Corp., Vice President-Clinical Development at Vertex Pharmaceuticals, Inc., Vice President-Clinical Research at Peptimmune, Inc., Chief Medical Officer & Executive Vice President at AMAG Pharmaceuticals, Inc., and Chief Medical Officer at Freeline Therapeutics Holdings Plc.
She completed her undergraduate degree from Brown University and her doctorate from The Warren Alpert Medical School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-06-20 | 0 ( -.--% ) | - $ | 2024-03-30 |
Julie Krop active positions
Companies | Position | Start |
---|---|---|
AQUESTIVE THERAPEUTICS, INC. | Director/Board Member | 2021-02-09 |
PURETECH HEALTH PLC | Chief Tech/Sci/R&D Officer | 2021-08-12 |
Puretech Health LLC
Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts. | Corporate Officer/Principal | 2021-09-30 |
Former positions of Julie Krop
Companies | Position | End |
---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 2021-07-31 |
AMAG PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-12-31 |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 2015-04-30 |
STRYKER CORPORATION | Corporate Officer/Principal | 2011-12-31 |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Chief Tech/Sci/R&D Officer | 2005-12-31 |
Training of Julie Krop
Brown University | Undergraduate Degree |
The Warren Alpert Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
PFIZER, INC. | Health Technology |
STRYKER CORPORATION | Health Technology |
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
AQUESTIVE THERAPEUTICS, INC. | Health Technology |
PURETECH HEALTH PLC | Health Technology |
Private companies | 5 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Puretech Health LLC
Puretech Health LLC Investment ManagersFinance Puretech Health LLC (PureTech Ventures) is a venture capital subsidiary of PureTech Health Plc founded in 2000 by Daphne Zohar, Robert Langer and Ben Shapiro. The firm is headquartered in Boston, Massachusetts. | Finance |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Julie Krop